Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Johnson & Johnson pauses COVID-19 vaccine production in Dutch plant

By Brian Buntz | February 8, 2022

JanssenJohnson & Johnson (NYSE:JNJ) has decided to temporarily suspend production of its COVID-19 vaccine in Leiden in the Netherlands to prioritize production of an investigational respiratory syncytial virus (RSV) vaccine, according to The New York Times.

The plant will resume production of its COVID-19 vaccine in a matter of months, the paper reported. The company is also working to enlist other facilities to help produce the vaccine, but they are either currently not operational or haven’t received regulatory approval.

While the J&J vaccine has failed to find widespread use in wealthy countries, it remains popular in portions of the developing world, including much of Africa. The vaccine has less-demanding storage requirements than the first generation of mRNA vaccines and offers robust protection against a range of variants when administered as a two-dose series.

Janssen COVID-19 vaccine

Image courtesy of Wikimedia Commons

At present, 11.3% of Africans are fully vaccinated, and 16.37% are fully vaccinated, according to the African CDC.

Production of the Janssen COVID-19 vaccine has also been diminished in the U.S. following a series of quality problems in a facility operated by Emergent Biosolutions (NYSE:EBS). Although production at that facility has resumed, the FDA hasn’t yet authorized the distribution of the recent vaccine doses produced at the facility.

Janssen also plans to tap additional plants to produce its COVID-19 vaccine, including a Merck facility in North Carolina and a plant from Biological E in India. Those plants, however, are not currently making the vaccine.

The Janssen COVID-19 vaccine was primarily developed at the Leiden facility.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Emergent Biosolutions
Emergent hid quality problems from FDA, House report concludes
World Changing Ideas
Fast Company 2022 World-Changing Ideas Awards highlight multiple pharma innovations
Pfizer logo
Pfizer ticks up on Street-beating Q1, lessens full-year guidance
Pfizer logo
Pfizer’s COVID-19 antiviral disappoints as post-exposure prophylactic 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards